BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sauerbruch T, Schierwagen R, Trebicka J. Managing portal hypertension in patients with liver cirrhosis. F1000Res 2018;7:F1000 Faculty Rev-533. [PMID: 29780579 DOI: 10.12688/f1000research.13943.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Selicean S, Wang C, Guixé-Muntet S, Stefanescu H, Kawada N, Gracia-Sancho J. Regression of portal hypertension: underlying mechanisms and therapeutic strategies. Hepatol Int 2021;15:36-50. [PMID: 33544313 DOI: 10.1007/s12072-021-10135-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Khalifa A, Rockey DC. Lower Gastrointestinal Bleeding in Patients With Cirrhosis-Etiology and Outcomes. Am J Med Sci 2020;359:206-11. [PMID: 32087941 DOI: 10.1016/j.amjms.2020.01.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yu S, Ericson M, Fanjul A, Erion DM, Paraskevopoulou M, Smith EN, Cole B, Feaver R, Holub C, Gavva N, Horman SR, Huang J. Genome-wide CRISPR Screening to Identify Drivers of TGF-β-Induced Liver Fibrosis in Human Hepatic Stellate Cells. ACS Chem Biol 2022;17:918-29. [PMID: 35274923 DOI: 10.1021/acschembio.2c00006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Petrisor A, Peagu R, Badiu DC, Stanescu AMA, Moldoveanu AC, Fierbinteanu -Braticevici C. Can Non-Invasive Methods Be Clinically Useful for Diagnosis and Severity of Portal Hypertension? Hepat Mon 2020;20. [DOI: 10.5812/hepatmon.99974] [Reference Citation Analysis]
5 Bochnakova T. Hepatic Venous Pressure Gradient. Clin Liver Dis (Hoboken) 2021;17:144-8. [PMID: 33868655 DOI: 10.1002/cld.1031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
6 Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Rep 2021;3:100316. [PMID: 34337369 DOI: 10.1016/j.jhepr.2021.100316] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
7 Kreisel W, Schaffner D, Lazaro A, Trebicka J, Merfort I, Schmitt-Graeff A, Deibert P. Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension. Int J Mol Sci 2020;21:E6223. [PMID: 32872119 DOI: 10.3390/ijms21176223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
8 Frigerio S, da Costa V, Costa M, Festari MF, Landeira M, Rodríguez-Zraquia SA, Härtel S, Toledo J, Freire T. Eosinophils Control Liver Damage by Modulating Immune Responses Against Fasciola hepatica. Front Immunol 2020;11:579801. [PMID: 33042162 DOI: 10.3389/fimmu.2020.579801] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Wu Y, Zhang M, Ni T, Zhang X, Wang R, Zhu L, Du J, Zhu Y, Zhao Y, Yang Y. Prognosis of systemic inflammation at an early stage of cirrhosis using the monocyte-to-lymphocyte ratio during malnutrition risk screening: a prospective cohort study. Postgrad Med 2022. [PMID: 35929972 DOI: 10.1080/00325481.2022.2110600] [Reference Citation Analysis]
10 Kabolowsky M, Nguyen L, Fortune BE, Santos E, Kishore S, Camacho JC. Interventional Management of Portal Hypertension in Cancer Patients. Curr Oncol Rep 2022. [PMID: 35953600 DOI: 10.1007/s11912-022-01319-8] [Reference Citation Analysis]